H.C. Wainwright raised the firm’s price target on Xeris Biopharma to $6 from $5.50 and keeps a Buy rating on the shares post the Q4 results. The company reported its sixth straight revenue beat, the analyst tells investors in a research note. The fir says the weakness in the stock post results is unmerited.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on XERS: